Choksi Laboratories holds EGM to approve convertible warrant issuance
- EGM held on October 17, 2026, via video conferencing
- Proposal for preferential issue of convertible warrants presented
- Promoters and proposed allottees abstained from voting
- Remote e-voting period ran from October 14 to October 16, 2026

*this image is generated using AI for illustrative purposes only.
Choksi Laboratories Limited convened an Extra Ordinary General Meeting (EGM) on October 17, 2026, to seek shareholder approval for issuing convertible warrants on a preferential basis. The meeting was conducted via video conferencing in compliance with regulatory guidelines.
The Board of Directors had previously approved the proposal for the preferential issue, subject to requisite compliances and member approval. This item was included as Special Business in the notice convening the EGM.
Voting and Participation Details
Remote e-voting was facilitated through the Central Depository Services (India) Limited platform for shareholders holding shares as of the cut-off date of October 10, 2026. The voting window opened on October 14, 2026, at 9:00 am and closed on October 16, 2026, at 5:00 pm.
A notable procedural aspect of the meeting was the abstention from voting by specific stakeholders. The Promoters and the proposed allottees in the preferential issue refrained from casting their votes on the resolution regarding the warrant issuance.
Meeting Proceedings
The meeting commenced at 12:33 pm and concluded at 12:39 pm. Mr. Sunil Choksi, Managing Director and Chairman, confirmed the presence of quorum and declared the meeting in order. Ms. Surbhi Agrawal, Practicing Company Secretary, served as the Scrutinizer to ensure a fair and transparent voting process.
All Directors, Key Managerial Personnel, and Auditors attended the virtual meeting. The Company Secretary provided an opportunity for registered shareholders to speak, though no further business was transacted before the meeting concluded with a vote of thanks.
Historical Stock Returns for Choksi Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | +6.72% | +1.20% | +105.74% | +21.60% | 0.0% |
Who are the specific allottees in the preferential issue, and what strategic value do they bring to Choksi Laboratories?
How will the capital raised from the convertible warrants be allocated across R&D, capacity expansion, or debt reduction?
What are the potential dilution impacts on existing minority shareholders once the warrants are fully converted?


































